Lanreotide vs Octreotide
A depot somatostatin analog, similar in action to octreotide. A long-acting somatostatin analog used to suppress GH and other hormones. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Lanreotide | Octreotide | |
|---|---|---|
| Also known as | Somatuline | Sandostatin |
| Type | Analog | Analog |
| Evidence | Established | Established |
| Family | Growth & repair | Growth & repair |
| Class | Somatostatin analog (cyclic octapeptide) | Somatostatin analog (cyclic octapeptide) |
| Receptor | Somatostatin receptors (SSTR2 and SSTR5 preferential) | Somatostatin receptors (SSTR2 and SSTR5 preferential) |
| Molecular weight | ~1,096.3 Da | ~1,019.2 Da |
| Half-life | depot-dominant (autogel acts over weeks) | |
| Based on | Somatostatin | Somatostatin |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Lanreotide and Octreotide?
- Lanreotide is an engineered analog based on Somatostatin; Octreotide is an engineered analog based on Somatostatin. Lanreotide signals at Somatostatin receptors (SSTR2 and SSTR5 preferential); Octreotide signals at Somatostatin receptors (SSTR2 and SSTR5 preferential).
- How do the half-lives of Lanreotide and Octreotide compare?
- The reported circulating half-life of Lanreotide is depot-dominant (autogel acts over weeks); Octreotide is ~1.5 h (subcutaneous; LAR depot ~monthly). These are reference values for the native or representative form — educational only, not dosing advice.
- Is Lanreotide the same as Somatuline?
- Somatuline is a brand name of Lanreotide. This comparison describes the molecules, not branded products.
Prefer the other order? Octreotide vs Lanreotide. Or open the interactive comparison tool to add more molecules.